In a Class of its Own!
Our lead candidate, CB-24, is a first-in-class cancer therapeutic, which has shown remarkable results in pre-clinical and early clinical studies. While the drug has shown to be well tolerated by patients, it has been proven in early studies to be highly toxic to various cancer cells, and has induced disease stabilisation, partial remission, and even complete remission in some patients.
The following video briefly explains why we are so excited about CB-24:
CB-24 Mechanism of Action
CB-24 (Crotoxin) is a heterodimeric neurotoxin composed of a non-enzymatic acidic subunit (crotapotin) and an enzymatically active phospholipase A₂ (PLA₂) subunit. Originally isolated from the venom of the South American rattlesnake Crotalus durissus terrificus, Crotoxin has been extensively studied for its biological effects, including antitumor activity.
CB-24 has a unique mechanism of action that differs from conventional chemotherapy or targeted therapy. It does not interfere with the DNA or metabolism of cells, but rather interacts with the cellular membrane of cancer cells. This makes it less toxic and more effective than existing treatments. Moreover, CB-24, and other neurotoxin based products in our suite, have a novel pattern of anti-cancer activity that is unlike any currently approved agents, making them a completely new category of molecular targeting therapies.
CB-24 and other snake venom derived proteins in our portfolio have a novel pattern of anti-cancer activity that is unlike any currently approved agents, making them a completely new category of molecular targeting therapies.